AlloMap心臟分子表達測試
K 號：K221640 · 2023-09-13
廣告
器材摘要
AlloMap Heart Molecular Expression Testing is the device name listed in this FDA 510(k) record. The listed applicant is Caredx, Inc.. It received FDA 510(k) clearance on 2023-09-13 under 510(k) number K221640. The device is classified under product code OJQ. It was reviewed by the CV advisory panel. FDA Decision: Substantially Equivalent.
常見問題
What is the AlloMap Heart Molecular Expression Testing?
AlloMap Heart Molecular Expression Testing is a medical device that received FDA 510(k) clearance on 2023-09-13. The listed applicant is Caredx, Inc.. The 510(k) number is K221640.
When did AlloMap Heart Molecular Expression Testing receive FDA 510(k) clearance?
AlloMap Heart Molecular Expression Testing received FDA 510(k) clearance on 2023-09-13, under 510(k) number K221640.
Who is the listed applicant for AlloMap Heart Molecular Expression Testing?
The FDA 510(k) record lists Caredx, Inc. as the applicant. This does not by itself establish the device manufacturer.
What is the FDA product code for AlloMap Heart Molecular Expression Testing?
The FDA product code for AlloMap Heart Molecular Expression Testing is OJQ.
相關臨床試驗
相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係，請查閱連結的官方來源。
官方來源
在 FDA 資料庫中查看 →資料來源為 FDA Open API。如需最新且權威的資訊，請始終參閱官方記錄。
廣告